米氮平联合氨磺必利治疗躯体化障碍疗效观察

The clinical effect observation of mirtazapine and amisulpride in somatization disorder

目的观察米氮平联合氨磺必利治疗躯体化障碍的疗效和安全性。方法将56例躯体化障碍患者随机分为研究组(米氮平联合氨磺必利)和对照组(米氮平),治疗观察8周,采用症状自评量表SCL-90中的躯体化因子、汉密尔顿焦虑量表HAMA评定疗效,副反应量表TESS评定不良反应。对比2组临床疗效。结果 2组治疗前及治疗后第1周末SCL-90中的躯体化因子量表评分比较差异无统计学意义(P>0.05),治疗后第2、4、8周2组SCL-90中的躯体化因子评分较治疗前均有显著下降,且研究组评分均低于对照组,差异均有统计学意义(P<0.01)。治疗前2组HAMA评分比较差异无统计学意义(P>0.05)。治疗后2组HAMA评分较治疗前逐渐下降,且研究组第2、4、8周HAMA评分低于对照组,差异有统计学意义(P<0.01)。2组临床疗效比较差异无统计学意义(P>0.05)。结论米氮平联合氨磺必利治疗躯体化障碍疗效好,不增加不良反应。

Objective To observe the clinical effect of mirtazapine and amisulpride in somatization disorder.Methods 56 cases patients with somatization disorder were randomly divided into research group and controlgroup. Research group treated by mirtazapine and amisulpride. Control group was treated by mirtazapine. 8 weeks later,compared the SCL-90 score,HAMA score and TESS score and clinical efficiency of 2 groups. Results The SCL-90 score of 2 group before treatment and 1weeks later after treatment has no statistically significant( P > 0. 05). The SCL-90 score 2,4,8 weeks after treatment were lower than that before treatment,and the research group was lower than those of control group,the difference was statistically significant( P < 0. 05). The HAMA score before treatment has no statistically significant( P > 0. 05). The HAMA Score after treatment of 2 group were lower than that before treatment,and the research group 2,4,8 weeks were lower than that of control group,the difference was statistically significant( P < 0. 05). The total efficiency of 2 groups was no statistically significant( P >0. 05). Conclusion Mirtazapine and amisulpride in somatization disorder has an good effect,no increase in adverse reactions.